GOG 162--PHASE III RANDOMIZED TRIAL OF CISPLATIN AND PACLITAXEL--OVARIAN CANCER

GOG 162——顺铂和紫杉醇的 III 期随机试验——卵巢癌

• 批准号: 6282251
• 负责人: PATRICIA S BRALY
• 金额: $ 1.97万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1999-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6282251
• 关键词: cis platinum compound; clinical research; combination chemotherapy; drug screening /evaluation; female; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; ovary neoplasms; paclitaxel

GOG 162: This protocol will examine the best way to safely give the two chemotherapy drugs cisplatin and taxol to treat subjects with advanced ovarian cancer. Approximately 5-10 patients will be enrolled locally. Patients will be randomly assigned to receive the chemotherapy drug Taxol over 24 hours or over 96 hours followed by the drug cisplatin. The standard method of giving Taxol is to inject it into a vein slowly over 24 hours, but there is some evidence that giving a slightly lower dose over a longer time may be more effective. Chemotherapy treatments will be repeated every 3 weeks for a total of 6 cycles unless there are excessive side effects or tumor is growing.

GOG 162：该方案将研究安全给予两种药物的最佳方法， 化疗药物顺铂和紫杉醇治疗晚期 卵巢癌 将在当地招募约5-10例患者。 患者将被随机分配接受化疗药物紫杉醇 超过24小时或超过96小时，然后是顺铂。 的 给予紫杉醇的标准方法是将其缓慢注射到静脉中， 24小时，但有证据表明，给予稍微低剂量 在更长的时间内可能会更有效。化疗治疗将 每3周重复一次，共6个周期，除非有 过度的副作用或肿瘤正在生长。